An observational study in Asthma, sponsored by AstraZeneca. Recruiting at 21 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by AstraZeneca · Observational
A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of Personalised Treatment Strategies in Chinese Population
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's planned enrollment of 355 is above the median of 150 across 970 observational studies indexed under Asthma.
Browse Asthma studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
A total of up to 355 participants will be recruited and enrolled into Cohort A (healthy participants), Cohort B (mild asthmatics), Cohort C (moderate to severe asthmatics), and Cohort D (Exacerbation asthmatics). Enrolment will be monitored to, 1) ensure at least 20 current smoker or ex-smoker in Cohort A; 2) ensure at least 40 male participants aged 40 years old or above in Cohort A.
Exclusion Criteria:
approximately 80 healthy participants
approximately 40 mild asthmatics on as-needed low dose inhaled corticosteroids (ICS)-formoterol, or low dose ICS plus as-needed short-acting β2 agonists (SABA), without the need for other controller medication.
approximately 160 moderate to severe asthmatics on low or medium dose ICS-long acting β2 agonists (LABA), high dose ICS alone or in combination with LABA .
approximately 75 asthmatics with protocol defined asthma exacerbation.
Descriptive summary of demographic and subject characteristic, clinical characteristics and functional deliverables.
Descriptive summary of demographic and subject characteristic, clinical characteristics and functional deliverables at baseline by study cohorts.
Time frame: At baseline
Descriptive summary of biomarker level.
Descriptive summary of biomarker level at baseline by study cohorts.
Time frame: At baseline
Statistical clustering of key biomarkers.
Statistical clustering of key biomarkers in moderate to severe asthma cohort.
Time frame: At baseline
FEV1 level
Evaluation of lung function via airway limitation
Time frame: At baseline
Forced Vital Capacity (FVC)
Evaluation of lung function via airway limitation
Time frame: At baseline
Maximal Mid Expiratory Flow (MMEF)
Evaluation of lung function via airway limitation
Time frame: At baseline
Airway remodeling
Evaluation of lung structure profile and change
Time frame: At baseline
Gas trapping
Evaluation of lung structure profile and change
Time frame: At baseline
Computed Tomography (CT) Scan
Evaluation of lung structure profile and change
Time frame: At baseline
Mean difference in the biomarker level.
Mean difference in the biomarker level between study cohorts
Time frame: At baseline
Statistical association between the biomarker and clinical disease outcomes.
Statistical association between the biomarker and clinical disease outcomes in each asthma cohort.
Time frame: From 2023-2025
Mean difference in the biomarker level between different tissues
Mean difference in the biomarker level between different tissues in each asthma cohort.
Time frame: From 2023-2025
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Sap
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca